Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 202.70

+3.3%

2:03 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bryce Elkins who wrote (18702)	4/6/1998 3:21:00 PM
From: Henry Niman	of 32384

Ble, I agree that the price will pop up soon. A representative from ZEN was just on CNBC to talk about Tamoxifen. The interview went about as I expected. Numbers were not available, but it sounded like they were as expected (on the plus and minus side). Thus there was no need to continue, because the risk/reward ratio was fairly well defined. The issue of blood clots was side-stepped and I'm not sure how serious the clots are, but they were fairly frequent. I think the numbers was about 1 in 100 so the number of patients developing blood clots would be higher than the number that did not get breast cancer. Moreover, a significant number would develop endometrial cancer. So there is a clear trade off. For every patient that doesn't get breast cancer, there are about two patients that develop endometrial cancer or blood clots from the "treatment". There is clearly room for improvement and the drug is clearly not appropriate for most women (those who enrolled were high risk - the general population would have a much poorer risk/reward ratio).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next